Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB305
- Development stage
- Preclinical
- Lead developer
- Jeune Aesthetics
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
**KB305** is a preclinical gene therapy candidate developed by Krystal Biotech for aesthetic skin conditions. It involves gene transference to deliver **type IV collagen**, a key extracellular matrix protein, aiming to replenish and restore skin structure for rejuvenation. Initially developed by Krystal Biotech, its global highest R&D status is preclinical, with potential applications in collagen replacement therapies for dermatological aesthetics.[7][9]
02
Targets
MYH9 (Non-muscle myosin IIA)COL4 (Collagen IV)
Beyond the preview
Go deeper on KB305.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KB305.